Epithelioid Mesothelioma: What the Cell Type Means for Your Prognosis - and Your Claim
About two-thirds of mesothelioma diagnoses are epithelioid - the cell type with the longest survival and the most treatment options. That matters medically first, but it also shapes how a legal claim is documented and valued.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What Epithelioid Mesothelioma Is
Mesothelioma - the cancer caused by asbestos exposure - comes in three cell types, and the type is determined by how the tumor cells look under a microscope.
Epithelioid is by far the most common: about 69% of cases in a SEER database study of 1,183 patients (Journal of Surgical Research, 2015), and 68% in a separate National Cancer Database cohort of 4,207 patients (2018). Sarcomatoid (~18-19%) and biphasic (~12-13%, a mix of both) make up the rest.
Epithelioid cells are uniform, divide more slowly, and stick together - which makes this type slower to spread and more responsive to treatment than the other two.
Case Details
The cell type is confirmed by biopsy and immunohistochemistry - a pathologist stains the tissue with marker panels (calretinin, CK5/6, WT-1, and others; no single marker is definitive). That pathology report does double duty: it guides your treatment, and it is core evidence in any asbestos claim, because it documents both the diagnosis and the subtype.
Prognosis: What the Studies Actually Show
Selected epithelioid subgroups do considerably better in published series: peritoneal epithelioid patients treated with cytoreductive surgery plus HIPEC have reported median survival around 51 months, and pleural patients with pleurectomy/decortication plus chemotherapy around 38 months (figures reported via secondary medical-legal sources citing AME Surgical Journal and Translational Lung Cancer Research - treat as reported ranges, not guarantees).
Treatment Options - Broadest of Any Cell Type
Epithelioid patients typically have the most treatment paths available:
• Surgery (extrapleural pneumonectomy or pleurectomy/decortication) - the cell type with the clearest documented survival benefit from resection.
• Chemotherapy - platinum + pemetrexed remains the standard backbone.
• Immunotherapy - Opdivo + Yervoy (nivolumab + ipilimumab), FDA-approved October 2, 2020 for unresectable pleural mesothelioma; in the CheckMate 743 trial median survival was 18.1 months versus 14.1 with chemo alone.
• Tumor Treating Fields (Optune Lua), FDA-approved May 2019 with chemo - 18.2 months median survival in the STELLAR study versus 12.1 historical control.
More viable treatment lines mean longer treatment histories - a fact that matters for the claim math below.
Why the Cell Type Matters for Settlement Value
From Diagnosis to Claim - the Typical Path
- 1
Biopsy Confirms the Diagnosis
Imaging raises suspicion, but only a tissue biopsy with immunohistochemistry confirms mesothelioma and identifies the cell type. Ask for a copy of the pathology report - you will need it for treatment decisions and any claim.
- 2
Staging and Treatment Planning
Epithelioid patients diagnosed early enough may qualify for surgery - the option with the largest documented survival benefit for this cell type (20.9 vs 14.7 months median, NCDB 2018).
- 3
Exposure History Is Reconstructed
Mesothelioma is caused by asbestos, typically decades before diagnosis. Work history, military service (especially Navy), union records and co-worker testimony establish which products and employers were involved.
- 4
Claims Are Filed
Depending on the exposure sources: lawsuits against solvent defendants, claims against asbestos bankruptcy trusts (60 trusts with about $37 billion in total assets per the GAO's 2011 report - the authoritative public figure), and VA benefits for veterans. Statutes of limitations run from diagnosis - usually 1-3 years depending on the state, so timing matters.
- 5
Resolution
Most mesothelioma claims settle rather than go to verdict, typically in negotiated stages per defendant. Trust claims pay on published schedules; lawsuit settlements depend on the strength of the exposure and medical record.
Watch Out For
High claim values attract aggressive middlemen. Three things to avoid:
Guaranteed-amount promises
Nobody can promise a number from a TV ad or a web form. Case value depends on your pathology, exposure record, and jurisdiction - anyone quoting a figure before seeing records is selling, not advising.
Medical advice from marketing sites
Cell-type statistics are population medians, not personal predictions. Treatment decisions belong with an oncologist - ideally at a center experienced in mesothelioma.
Fee confusion
Mesothelioma firms work on contingency (typically 33-40% plus costs). Nothing is owed up front; get the percentage in writing before signing.
Epithelioid Mesothelioma - FAQ
What percentage of mesothelioma is epithelioid?
About 69% in the SEER cohort (1,183 patients, 2015) and 68% in the National Cancer Database cohort (4,207 patients, 2018). The American Cancer Society cites a 50-70% range. It is by far the most common cell type.
Is epithelioid mesothelioma curable?
There is no cure, but epithelioid has the best outlook of the three cell types, and selected patients - especially those eligible for surgery or multimodal therapy - live substantially longer than the overall medians. Discuss your individual staging with a mesothelioma specialist.
What is the life expectancy for epithelioid mesothelioma?
Median survival across large cohorts is about 14 months - rising to about 21 months with surgical resection (NCDB 2018). Published series for selected subgroups (peritoneal disease with HIPEC; P/D plus chemo) report substantially longer medians. These are population statistics, not individual predictions.
How is the cell type determined?
Through biopsy plus immunohistochemistry: pathologists apply marker panels (calretinin ~94% sensitivity, CK5/6 ~90%, WT-1 ~81%, plus epithelial markers such as MOC-31 and Claudin-4). No single marker decides it - the panel does.
Does epithelioid mesothelioma pay a higher settlement?
No published data proves a per-cell-type price difference, and we won't pretend otherwise. What is documented: case value factors include disease type and severity, and epithelioid patients typically accumulate longer treatment histories and longer remaining life expectancy - both of which increase the documented damages a claim is built on.
Is biphasic mesothelioma treated like epithelioid?
Biphasic tumors contain both cell types (by convention at least 10% of each); prognosis and treatment response generally track the dominant component. Median survival in the large cohorts was 9.5-10 months - between epithelioid and sarcomatoid.
What should I bring to a legal consultation?
The pathology report (with cell type), imaging and treatment records, and the best work/service history you can reconstruct - employers, job sites, years, and products you remember. Firms handle the rest of the investigation at no upfront cost.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.